Loading company…
Nuoshan Technology develops microfluidic organ chips for preclinical research and cancer drug sensitivity testing.
Founded in 2024 in Beijing, Nuoshan Technology develops microfluidic organ chips for preclinical research. Its team includes members from Beijing Institute of Technology and Peking Union Medical College Hospital. The company completed a chip prototype and conducted a clinical cohort study of chip-based cancer drug sensitivity testing at the hospital. In March 2024, it raised CNY 10 million in angel funding from Tianjin Huakong Dianke Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in